SCHEMBL7793487

SCHEMBL7793487

CN(Cc1ccccc1)C(=O)c1cnc2c(N)cccc2c1N(C)C

nearest known ligand 0.46

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.46
HPGD P15428 1/20 0.45
MEN1 O00255 2/20 0.44
ALDH1A1 P00352 2/20 0.44
CTSG P08311 1/20 0.42
RPS6KB1 P23443 1/20 0.42
KDM4E B2RXH2 1/20 0.41
HSP90AA1 P07900 1/20 0.41
TACR1 P25103 1/20 0.41
LMNA P02545 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MAPT P10636 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6537761 0.75 KMT2A (0.53) KMT2AMEN1ALDH1A1KDM4ELMNA
SCHEMBL12260892 0.72 KMT2A (0.61) KMT2AHPGDMEN1ALDH1A1KDM4E
SCHEMBL7803244 0.70 ALDH1A1 (0.48) KMT2AHPGDMEN1ALDH1A1KDM4E
SCHEMBL21101074 0.70 BCAT2 (0.45) KMT2AMEN1ALDH1A1RPS6KB1SMN1; SMN2
SCHEMBL21101402 0.69 KMT2A (0.44) KMT2AHPGDMEN1ALDH1A1KDM4E
SCHEMBL28927152 0.69 KMT2A (0.54) KMT2AHPGDMEN1ALDH1A1HSP90AA1
SCHEMBL30315950 0.69 KMT2A (0.54) KMT2AHPGDMEN1ALDH1A1HSP90AA1
SCHEMBL15659195 0.68 PSMD14 (0.61) KMT2AHPGDMEN1ALDH1A1HSP90AA1
SCHEMBL11942319 0.68 KMT2A (0.59) KMT2AHPGDMEN1ALDH1A1KDM4E
SCHEMBL20702345 0.66 MMP1 (0.49) KMT2AHPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010001101-A1 Phenanthroline derivatives ZENECA LIMITED 2001-05-10 US disclosed
EP-1027351-A1 PHENANTHROLINE DERIVATIVES FIBROGEN, INC. (US) 2000-08-16 EP disclosed
US-5916898-A ANTIFIBROPROLIFERTIVE, ENZYME INHIBITORS OF PYROLYL 4-HYDROXYLASE, ANTIARTHRITIC AGENTS ZENECA LIMITED (GB) 1999-06-29 US disclosed
WO-1999021860-A1 PHENANTHROLINE DERIVATIVES FIBROGEN, INC. (US) 1999-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010001101-A1 Phenanthroline derivatives H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, COL1A1, COL2A1 KMT2A 1250/4885HPGD 802/4885MEN1 2187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.